Tweet
<img alt="" height="1" width="1" />
Vical Shares Fall Most in 20 Years on Cancer Drug Results
Bloomberg
Vical Inc. (VICL), the maker of experimental cancer drugs, fell the most in 20 years after saying its melanoma medicine failed to help patients in a clinical trial. Shares of Vical plunged 60 percent to $1.45 at 9:39 a.m. in New York trading, after falling as much as ...
Vical drops cancer therapy after trial failure, shares plungeReuters
Vical to Terminate Allovectin Program After Study Fails to Meet EndpointsWall Street Journal
Vical Scraps Melanoma Candidate After Phase III FailureGenetic Engineering News
MarketWatch -FierceBiotech
all 16 news articles »
More...